CompletedNot Applicable

LuCID - Investigating the Use of a Novel Digital Rectoscope for Community Examinations During COVID-19

United Kingdom114 participantsStarted 2020-11-14

Plain-language summary

The LumenEye scope and CHiP platform will be piloted in a number of clinical settings including remote colorectal clinics. The rationale is to perform an initial pilot study to determine the clinical utility of the LumenEye device for use in primary and secondary care settings. The main hypothesis is that digital rectoscopy is safe and acceptable to clinicians including general practitioners and can significantly reduce the burden of endoscopy referral to and within secondary care centres.

Who can participate

Age range18 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * Patients aged 18 and over * Patients with any of the following: * Positive Faecal occult blood test / Faecal immunochemical test (FIT) * Positive faecal calprotectin. * Established history of polyps and/or adenomas * 2WW patients referred to a colorectal clinic * Known IBD patients with flare symptoms * Patients with a suspected new diagnosis of IBD Exclusion Criteria: * Inability to consent * Inability to communicate effectively in English * Pregnancy * Unfit for bowel preparation * Anal stricture * Allergy to plastic * Inability to lie flat for more than 10 minutes

What they're measuring

Patient Experience of LumenEye Examination

Timeframe: On the day of examination

Clinician Experience of LumenEye Examination

Timeframe: On the day of examination

Trial details

NCT IDNCT05043363

SponsorImperial College London

Sponsor typeOTHER

Study typeOBSERVATIONAL

Primary completion2021-06-05

Results submitted2022-08-04

View on ClinicalTrials.gov More Bowel Cancer trials